Germany’s Federal Joint Committee has begun a renewed assessment of Imlifidase, a medicine used for desensitisation in kidney transplantation. Its brand name is Idefirix, and its marketing authorisation holder is Hansa Biopharma AB.
The procedure began on 15 October 2026. Imlifidase is designated an orphan drug for the treatment of a rare disease.
The benefit assessment and the start of the written consultation are scheduled for publication on 15 January 2027. The deadline for written comments is 5 February.
